Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03459794 · ClinicalTrials.gov registry record · Early Phase 1
Ivermectin and Human Immunity
A Early Phase 1 study, sponsored by University of Georgia.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
NCT03459794 is a Early Phase 1 study that has completed, run by University of Georgia. The registered enrollment target is 12 participants.
The verdict
NCT03459794, a Early Phase 1 study, has completed, sponsored by University of Georgia.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
We hypothesize that ivermectin, a drug used to treat parasitic worm infections, interacts with the human innate immune system and that this contributes to its anti-parasitic effects. Participants will donate blood before and after being administered the normal human dose of the drug. We will compare the cell types present in the blood and the chemicals known to influence the human immune system before and after the drug is given, as well as measuring any changes in gene expression in white blood cells 4 and 24hrs after the drug is taken.
Interventions
- OTHER Placebo
- DRUG Ivermectin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-02-12 |
| Est. Completion | 2018-11-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03459794
The ClinicalTrials.gov registry entry for NCT03459794 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Georgia, which has 59 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03459794 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03459794 about?
NCT03459794 is a clinical study titled "Ivermectin and Human Immunity". We hypothesize that ivermectin, a drug used to treat parasitic worm infections, interacts with the human innate immune system and that this contributes to its anti-parasitic effects. Participants will donate blood before and after being administered the normal human dose of the drug. We will compare...
What is the current status of trial NCT03459794?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2018-02-12. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT03459794?
The interventions under investigation include: Placebo (OTHER), Ivermectin (DRUG).
Who is sponsoring clinical trial NCT03459794?
This trial is sponsored by University of Georgia, which has 59 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.